PCSK9 Forum
17th July 2015
Facebook Twitter RSS YouTube
For latest updates
Register today
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
Challenges of FH
Challenges of FH
Better detection and improving care
The Dutch promise

Recent research has highlighted the serious clinical consequences of familial hypercholesterolaemia (FH) for cardiovascular (CV) risk in thousands of people - many of whom are unaware of their condition.

A recent European survey (EUROASPIRE IV) of secondary prevention patients showed that 8.3% of those who had experienced a heart attack were suffering from FH.

In younger patients (<50 years) FH was believed to occur in one in five heart attack victims.

See video »
Dutch experience
Improving detection and care

In Europe, The Netherlands has proved that a concerted and integrated effort delivers effective detection of families at risk through cascade screening which combined with early treatment significantly improves the prognosis of people with FH.

Dr Peter Lansberg, founder and former Director of the Dutch National FH Cascade Screening Programme, discusses the Dutch experience.

He emphasises the importance of gaining the active participation of patient advocacy organisations and government.

Dr Peter Lansberg
Department of Vascular Medicine
Academic Medical Center

Watch the interview   Listen to the Podcast
Watch the interview Listen to the Podcast
Start treatment early: Maximise benefit

FH is the most common inherited disease in the world - affecting about 30 million people globally - of whom only about 1% have been diagnosed.

Therefore, it is critically important there is a global effort to start treatment early to prevent children ever developing atherosclerosis.

This strategy could “virtually eliminate” heart attacks in this population, according to Professor Frederick Raal of the University of Witwatersrand, Johannesburg, South Africa.

Watch the video » Watch more programmes »
Watch the interview
In the news

PCSK9 inhibitors and new onset diabetes - Reassuring evidence

Reassuring data have been released suggesting that PCSK9 inhibition does not increase the risk of new onset diabetes in statin treated patients.

Read the article by Dr Bertrand Cariou »

Plasma PCSK9 levels not associated with metabolic risk

While elevated PCSK9 levels are not associated with increased metabolic risk, an increased ratio of PCSK9/apoB does predispose to higher risk.

Read the article »

Safety of LDL-lowering in FH children

One of the questions raised about managing children with familial hypercholesterolaemia (FH, inherited high cholesterol) is the long term safety of cholesterol-lowering treatments. There has been some concern that lowering cholesterol levels could interfere with hormone production and, potentially, future fertility.

Read the article »
Easy access to e-book
Understanding PCSK9 inhibition
Free for healthcare professionals

Prepared by independent experts from PCSK9 Education and Research Forum.

Available free to registered members of the Forum.

Register and read online »    Download now »
PCSK9 Inhibition Handbook
Invite colleagues to listen to the podcasts and read the introductory guide by joining the PCSK9 Forum

Forward to your colleagues now »
Like us on Facebook
For the latest updates on conferences, PCSK9 news and video reports.
Follow us on Twitter
For updates on hot topics,
PCSK9 news and conference reports.
YouTube Channel
For the latest videos, interviews and webcasts from leading experts.
Supported by educational grants from: Amgen Lilly pFizer Sanofi
Copyright PCSK9 Forum 2015. Please click here to unsubscribe from future mailings.